Kidney Cancer (Renal Cell Carcinoma): Symptoms, Diagnosis, Treatment & Red Flags

In adult oncology, “kidney cancer” almost always refers to renal cell carcinoma, a malignancy that arises from the epithelium of the renal cortex—most often the proximal convoluted tubule for the dominant clear-cell subtype. Less common adult primaries include papillary RCC, chromophobe RCC, collecting-duct carcinoma, and rarer translocation-associated tumours; transitional-cell (urothelial) cancers of the renal pelvis are a separate biological entity managed under upper-tract urothelial pathways. In children, the most common renal malignancy is Wilms tumour (nephroblastoma), which behaves and is staged differently and is not the focus of this article.

Pathophysiology in clear-cell RCC centres on disruption of the von Hippel–Lindau (VHL) tumour-suppressor pathway, leaving cells unable to degrade hypoxia-inducible factors. Persistent HIF activity drives angiogenesis (via VEGF), glycolysis, and tumour growth—the same biology that makes anti-angiogenic tyrosine-kinase inhibitors and combination immune-checkpoint therapy effective. Tumours often grow slowly within the renal capsule, then invade the renal vein, perinephric fat, or adjacent organs. Lung, bone, liver, brain, and the contralateral kidney are typical metastatic destinations, and disease can recur years after apparent surgical cure.

Two parallel frameworks shape decisions. TNM staging (AJCC/UICC, currently 8th edition) describes anatomy: tumour size, perinephric and venous invasion, regional nodes, and distant metastases. IMDC risk stratifies metastatic disease using six routinely available variables; combined IMDC favourable, intermediate, and poor groups predict survival and influence first-line systemic-therapy choice.

TNM (kidney) — clinical short form

↔On a small screen, swipe or scroll sideways to see the full table.

IMDC risk variables (each adverse factor scores 1)

• Karnofsky performance status < 80%.
• Time from diagnosis to systemic therapy < 1 year.
• Anaemia: haemoglobin below the lab lower limit.
• Hypercalcaemia: corrected serum calcium above the upper reference limit.
• Neutrophilia above the upper reference limit.
• Thrombocytosis above the upper reference limit.

*Apply the staging edition your tumour board uses. IMDC risk is intended for metastatic disease — favourable = 0 factors, intermediate = 1–2, poor = ≥3 — and is recalculated whenever therapy lines change.

Most contemporary kidney cancer is found incidentally on cross-sectional imaging requested for unrelated complaints; a minority still presents with the classic triad. Bedside teams should keep a low threshold when constitutional symptoms cluster with subtle renal-tract clues.

Common features

• Painless visible haematuria (often intermittent, sometimes with clot colic).
• Persistent flank or abdominal pain, dull and unrelated to movement.
• Palpable abdominal or flank mass on examination.
• Fatigue and reduced exercise tolerance, often disproportionate to anaemia severity.
• Low-grade fever or night sweats with no infective source.

Atypical / late presentations

• Unilateral varicocele in an adult man (especially right-sided) suggesting renal-vein/IVC tumour thrombus.
• New-onset bilateral lower-limb oedema with abdominal venous distension—possible IVC obstruction.
• Bone pain or pathological fracture from osteolytic metastasis—correlate with elevated serum calcium.
• Persistent dry cough or haemoptysis from pulmonary metastases.
• Unexpected polycythaemia or normocytic anaemia not matching obvious GI losses.

RCC is mainly a sporadic disease, but a constellation of modifiable and inherited factors raises risk meaningfully. Around 4–8% of cases are linked to hereditary syndromes, which matters for counselling and family screening.

Modifiable contributors

• Cigarette smoking — graded dose–response with risk falling slowly after cessation.
• Obesity (raised BMI) and metabolic syndrome.
• Long-standing, especially poorly controlled, hypertension.
• Occupational exposures, notably trichloroethylene and certain heavy metals.

Non-modifiable / structural risk

• End-stage renal disease and acquired cystic disease in patients on prolonged dialysis.
• Hereditary syndromes — Von Hippel–Lindau (clear-cell RCC), hereditary papillary RCC (MET), Birt–Hogg–Dubé (FLCN), hereditary leiomyomatosis and RCC (FH), tuberous sclerosis.
• Family history of RCC in a first-degree relative — consider clinical genetics referral when bilateral or early-onset disease appears.

Workup balances confirming malignancy, defining anatomy for surgery, and quantifying disease burden for systemic-therapy planning. Multidisciplinary input (urology, radiology, medical oncology, pathology) is the standard from referral onwards.

Bedside & primary-care assessment

• Targeted history covering haematuria episodes, flank pain, smoking, occupational exposure, family RCC, and weight trend.
• Examination including BP, abdominal palpation, lymph-node survey, scrotal exam in men, and bone tenderness sweep.
• Bedside dipstick to confirm haematuria; do not let a clear dipstick override visible bleeding history.

Laboratory investigations

• Full blood count and differential — look for anaemia or polycythaemia.
• Comprehensive metabolic panel, with focus on creatinine and calcium.
• Liver function tests — paraneoplastic Stauffer pattern can mimic metastasis.
• LDH if metastatic disease is suspected; coagulation panel before any biopsy or surgery.
• Urinalysis with microscopy, plus urine cytology when an upper-tract urothelial cancer is also possible.

Imaging strategy

• Multiphase contrast-enhanced abdominal/pelvic CT — first-line for a suspected renal mass; characterises enhancement, perinephric extension, and venous involvement.
• MRI for indeterminate masses, contrast contraindications (e.g. severe renal impairment or contrast allergy), or assessment of IVC tumour thrombus extent.
• Chest X-ray for low-risk staging, with chest CT when nodules, large primaries, or symptoms warrant it.
• Bone imaging (e.g. bone scan) only if symptoms or biochemistry suggest skeletal involvement; brain MRI when neurological signs emerge or before some systemic therapies in advanced disease.

Renal-mass biopsy

Biopsy is selective—appropriate before ablation, before systemic therapy where histology is needed, in indeterminate small masses considered for surveillance, or when metastasis from another primary is plausible. It is not mandatory before surgery for a mass that looks classically malignant on imaging when the team plans curative resection.

1. Stabilise haematuria, hypertension, calcium, and analgesia—do not allow a frank-bleeding patient to drift.
2. Characterise the lesion: size, enhancement, perinephric extension, venous invasion, nodal status.
3. Stage the disease with chest imaging and targeted bone/brain studies as indicated.
4. Risk-stratify metastatic disease with IMDC and document Karnofsky performance.
5. Decide nephron-sparing surgery, radical nephrectomy, ablation, or surveillance based on T-stage, anatomy, and renal reserve.
6. Sequence systemic therapy in metastatic disease with IO ± TKI combinations per current pathway.
7. Surveillance with structured imaging and renal-function checks—frequency depends on stage and risk.

Several conditions overlap with RCC presentations, especially when haematuria, flank pain, or a renal mass anchors the picture. Imaging characteristics, infection markers, and history usually separate them.

↔On a small screen, swipe or scroll sideways to see the full table.

Subtype shapes prognosis and systemic-therapy choices. Pathology reports usually include WHO/ISUP grade, sarcomatoid or rhabdoid features, and necrosis—each refines outlook.

• Clear-cell RCC (≈70–80%): the dominant adult subtype; VHL-driven, generally responsive to anti-angiogenic and immune-checkpoint therapy.
• Papillary RCC (≈10–15%): often multifocal; type 1 typically less aggressive than type 2; MET-pathway implications.
• Chromophobe RCC (≈5%): usually indolent with favourable prognosis when localised.
• Collecting-duct & medullary carcinoma (rare): aggressive courses; medullary RCC linked to sickle-cell trait.
• Translocation-associated RCC: younger patients; Xp11/TFE3 family fusions.
• Sarcomatoid / rhabdoid features: not a separate subtype but a high-risk modifier; influences IO-based therapy decisions.

Therapy is tailored to stage, comorbidity, renal reserve, and patient preference. Decision-making is multidisciplinary and re-revisited at each disease milestone.

Localised disease

• Active surveillance for small (<4 cm) renal masses, especially in older adults or those with significant comorbidity—interval imaging plus selective biopsy guides escalation.
• Partial nephrectomy (open, laparoscopic, or robotic) — preferred where oncologically and anatomically feasible to preserve nephrons and long-term renal function.
• Radical nephrectomy for larger or anatomically complex tumours, those with venous extension, or where partial surgery is not safe.
• Thermal ablation (cryoablation or radiofrequency) — selected small renal masses in patients with comorbidity precluding surgery.

Adjuvant therapy

• Adjuvant pembrolizumab is offered in high-risk resected clear-cell RCC per current pathways; balance benefit against immune-related adverse events with the patient.
• Routine adjuvant tyrosine-kinase inhibitor therapy is no longer standard — confirm against the local protocol your service follows.

Advanced and metastatic disease

• IO + IO doublet (e.g. nivolumab plus ipilimumab) — option in IMDC intermediate/poor-risk clear-cell RCC.
• IO + TKI combinations (e.g. pembrolizumab–axitinib, pembrolizumab–lenvatinib, nivolumab–cabozantinib, avelumab–axitinib) — used across IMDC risk groups depending on local availability and patient factors.
• TKI monotherapy (sunitinib, pazopanib, cabozantinib, axitinib, tivozanib) — for patients unsuitable for IO or in subsequent lines.
• Cytoreductive nephrectomy in selected fit metastatic patients, integrated with systemic therapy plans.
• Stereotactic body radiotherapy for symptomatic bone or oligometastatic deposits.

Special populations

• Patients with a single kidney or pre-existing CKD — favour nephron-sparing approaches and involve nephrology early.
• Hereditary syndromes (e.g. VHL) — multifocal, recurrent disease; consider HIF-2α inhibitor pathways and lifelong specialist surveillance.
• Older adults with frailty — surveillance or ablation may outweigh major surgery; document shared decision-making.

Disease-driven

• Tumour bleeding, retroperitoneal haemorrhage, urinary obstruction.
• Renal-vein or IVC tumour thrombus with risk of embolism.
• Bone metastases with pathological fracture or spinal-cord compression — bone pain warrants prompt review.
• Paraneoplastic syndromes — hypercalcaemia of malignancy, polycythaemia, secondary AA amyloidosis, Stauffer syndrome.

Therapy-related

• Postoperative bleeding, urinoma, ileus, acute kidney injury after partial nephrectomy.
• Long-term decline in eGFR and proteinuria after radical nephrectomy.
• TKI toxicities (hypertension, hand-foot skin reaction, hepatotoxicity, hypothyroidism); manage hypertension with first-line agents and add furosemide only when fluid overload coexists.
• Immune-related adverse events from checkpoint inhibitors — colitis, pneumonitis, hepatitis, endocrinopathies, myocarditis.

There is no population-wide screening programme for RCC, so prevention is largely about modifiable risk reduction and structured surveillance for high-risk individuals: support tobacco cessation, weight management, and tight blood-pressure control; review the medication list when long-term analgesics or nephrotoxins are stacked. For people with hereditary syndromes such as Von Hippel–Lindau, hereditary papillary RCC, Birt–Hogg–Dubé, hereditary leiomyomatosis-RCC, or tuberous sclerosis, refer to clinical genetics for risk-tailored imaging programmes. Patients on prolonged dialysis with acquired cystic disease should be monitored according to local renal-unit protocols.

Outcome depends sharply on stage at diagnosis, histology, grade, sarcomatoid features, and IMDC risk for metastatic disease. Five-year survival for localised RCC is reported around 90% in major registries, falling stepwise with regional spread and into the low double-digits for distant metastatic disease. Outlook in metastatic RCC has improved substantially with IO-based combinations, but heterogeneity is large; share realistic expectations and trial-eligibility options with patients during MDT discussions.

Outside specialist urology centres, most clinicians meet kidney cancer at three points: someone presenting with painless visible haematuria, an incidentally found renal mass on imaging requested for another problem, or a complication on a patient already in active treatment. The single highest-yield habit is to stop and ask whether the current symptom or test result fits an oncological cause—any one of polycythaemia, hypercalcaemia, persistent low-grade fever, or unexplained anaemia can be the first usable clue. Document timelines crisply, name the chemo/oncology phone line in handovers, and keep a copy of the patient’s drug schedule on the chart so out-of-hours teams can spot interactions before they bite.

• NEWS2 vitals on schedule, with at-home BP log if on TKIs.
• Hourly urine output and fluid balance for the first 48 h after partial nephrectomy or in any AKI risk window.
• Hb trend, platelet count, and creatinine each shift in the immediate post-operative phase.
• Pain score and analgesia ladder; document anti-emetic timing on chemotherapy days.
• Skin and oral cavity checks for hand-foot reaction and mucositis on TKIs; stool diary on IO therapy.
• Bone-pain screen, palpation of the operative site for collections or expanding haematoma.

• Heavy haematuria with clots and hypotension or syncope.
• Sudden severe flank or abdominal pain with shock — possible tumour rupture or large haemorrhage.
• New chest pain, breathlessness, hypoxia, or unilateral leg swelling — pulmonary embolism risk is elevated.
• Fever ≥ 38 °C with neutropenia on systemic therapy — neutropenic sepsis pathway.
• New focal neurological deficit, seizures, or thunderclap headache — exclude brain metastasis or haemorrhage.
• Severe diarrhoea, jaundice, persistent dry cough or new dyspnoea on immune-checkpoint inhibitors — possible high-grade immune-related adverse event.

Trigger the local oncology emergency or rapid response pathway when NEWS2 climbs sustainably, mean arterial pressure falls more than 20 mmHg below the patient’s usual baseline despite fluids, urine output drops below 0.5 mL/kg/h, haemoglobin falls more than 20 g/L from postoperative baseline, or new hypoxia, oliguria, or confusion appears. Run a structured sepsis screen when fever or rigors emerge on any anti-cancer therapy; bring the most recent imaging report, drug chart (TKI/IO doses, last steroid administered), and operative note to senior review—knowing whether the patient had a partial or radical nephrectomy and how many days post-op they are changes the differential immediately.

Pre-treatment

• Confirm consent, fasting status, antiplatelet/anticoagulant plan, and group-and-save for surgical patients.
• Document baseline weight, BP, and renal function so trends are interpretable post-operatively.
• Provide structured information on the planned procedure or systemic therapy, including realistic side-effect timelines.
• Coordinate pain assessment training for self-monitoring at home where outpatient TKI/IO therapy is planned.

Active treatment

• For surgery: monitor wound site, drains, urinary catheter, ileus signs, and early mobilisation milestones; track eGFR and electrolytes daily on the inpatient pathway.
• For TKIs: daily home BP, weekly weight, document any new diarrhoea, hand-foot reaction, mucositis, or fatigue with date of onset.
• For checkpoint inhibitors: stool diary, oxygen saturation if respiratory symptoms emerge, scheduled thyroid and liver-function bloods per protocol.
• For radiotherapy: skin-care plan and bone-protective referral when treating skeletal metastases.

Red flags to escalate

• Falling Hb with rising HR or hypotension after partial nephrectomy.
• Frank haematuria with clots blocking the catheter or causing colicky pain.
• Sustained systolic BP > 170 mmHg or symptomatic hypertensive episode on TKIs.
• ≥ 6 stools/day above baseline, blood in stool, or new dyspnoea on IO therapy.
• New confusion, focal neurology, or seizure—exclude metastasis or metabolic cause.

Education & evaluation

• Walk through sick-day rules and the chemotherapy hot-line number; check teach-back understanding.
• Reinforce the importance of declaring kidney cancer history to dental, surgical, and out-of-hours teams.
• Plan structured surveillance imaging and renal-function follow-up after curative surgery; review survivorship needs (psychological, financial, return-to-work).

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of renal cell carcinoma evaluation, peri-operative partial-nephrectomy care, and tyrosine-kinase / immune-checkpoint stewardship in kidney cancer. Tap Check answers for the rationale layer.